- Home
- SOUN vs EWTX Comparison
SOUN vs EWTX Comparison
Compare SOUN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOUN | EWTX |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | 954 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SOUN | EWTX |
|---|---|---|
| Price | $7.11 | $34.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $15.00 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 22.6M | 1.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $40.76 | N/A |
| Revenue Next Year | $20.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.83 | $12.31 |
| 52 Week High | $22.17 | $40.77 |
Technical Indicators
Market Signals| Indicator | SOUN | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 50.54 |
| Support Level | $6.02 | $27.81 |
| Resistance Level | $9.19 | $35.00 |
| Average True Range (ATR) | 0.52 | 1.98 |
| MACD | -0.20 | -0.10 |
| Stochastic Oscillator | 12.50 | 30.88 |
Price Performance
Historical ComparisonAbout SOUN SoundHound AI Inc
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.